If marijuana is moved from Schedule 1 to Schedule 3 of the Controlled Substances Act, that would expand both access and product selection for medical marijuana patients. But rescheduling likely wouldn’t impact how state-regulated MMJ dispensaries operate. “Schedule 3 allows essentially a new pathway for cannabis to be in the marketplace, which is through an FDA-approved drug channel,” said Amy Rubenstein, a partner with the international law firm Dentons. Pharma pipeline Rubenstein explained that moving marijuana to Schedule 3 would make it… Read more.
Your daily dose of news & information.
As the holiday season approaches, retailers must strategically prepare to capitalize on the most festive time of year. Looking back at last year’s holiday cannabis sales, we witnessed an undeniable trend in consumption: The top-selling products included a mix of top-shelf and classic flower strains, 1g distillate cartridges, and indica gummies. The demand for these products soared during the holidays, leading to a remarkable 34-percent increase in average basket size during the week of Thanksgiving and an 11-percent increase in… Read more.
In nearly every state, the trend is the same: As cannabis products are introduced to a newbie consumer market, flower sales start off strong before extracts and edibles slowly but surely start grabbing a bigger piece of the pie. That said, flower still reigns supreme in every state. Its market share may have decreased over time, but the amount of money consumers spend on flower has increased every year. Total flower sales in 2022 were just over $14 billion, according… Read more.